Halozyme Therapeutics, Inc. revised earnings guidance for the year 2022. For the year, the company expects total revenue of $655 million to $685 million, an increase from prior guidance range of $530 million to $560 million, representing growth of 48% to 55% over 2021 total revenue primarily driven by projected revenue contribution from the Antares business of $115 million to $125 million. Operating income of $240 million to $265 million, a decrease from prior guidance range of $350 million to $380 million, representing a decline of 4% to 13% over 2021 operating income.

GAAP net income of $170 million to $195 million, a decrease from prior guidance range of $270 million to $295 million. GAAP diluted earnings per share of $1.20 to $1.35, a decrease from prior guidance of $1.90 to $2.05, due to acquisition related costs in 2022.